Hibercell Is A Clinical Stage Biotechnology Company Based In New Yorkfounded In 2019The Company Is Dedicated To Developing Novel Therapeutics That Address Treatment Resistancecancer Relapseand Metastasis In Cancer Patientswith Significant Backing From Arch Venture Partners And Other Life Science Investorshibercell Aims To Improve Patient Outcomes By Leveraging Insights From Stress Responses In Cancer Cells The Company S Therapeutic Pipeline Includes Hc 7366A First In Human Candidate That Activates The Gcn2 Kinaseand Hc 5404Which Targets The Perk Kinase And Is In Phase 1A Clinical Trialsadditionallyodetiglucan Is In Phase 2 Clinical Development And Modulates The Anti Tumor Innate Immune Responsehibercell Also Employs Advanced Technologiesincluding Ai And Machine Learningto Analyze Tumor Data And Identify Potential Therapeutic Targetsjonathan Lanfear Serves As The President And Ceoguiding The Company S Strategic Direction And Research Initiatives
